table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 all comers
COVID 19 all comers
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment LIFESAVER
Immunosuppressants drugs
anti-interleukin-6
sarilumab
sarilumab high dose (400mg) sarilumab phase 2 high dose
sarilumab low dose (200mg) sarimulab phase 2 low dose
tocilizumab BACC Bay Tocilizumab Trial TOCOVID
janus kinase (JAK) inhibitor
baricitinib RECOVERY
leflunomide Wang
antiviral and associated therapy
chloroquine and derivatives
chloroquine Chen, ChiCTR2000030054 - Chloroquine
hydroxychloroquine NOR-Solidarity ... IRCT20150808023559N20 ChiCTR2000030054-HCQ ... IRCT20150808023559N20
darunavir cobicistat Jun C
favipiravir Chang Chen et al. NCT04310228-FAVI ... Lou ... IRCT20150808023559N20 jRCTs041190120 IRCT20150808023559N20
nirmatrelvir / ritonavir (Paxlovid) EPIC-SR
remdesivir Norwegian NOR study ... Andreas ...
umifenovir (arbidol) ELACOI ...
miscellaneous
aviptadil COVID-AIV
camostat mesilate Gunst JD
Renin-angiotensin-system-acting agents
angiotensin receptor blockers (ARBs)
losartan University of Minnesota

6 studies excluded by filtering options 1

5092 Yang, 2020 1133not a RCThigh risk of bias
5228 Bean, 2020 1193not a RCThigh risk of bias
5295 Zhang, 2020 1133not a RCThigh risk of bias
5331 Li, 2020 1134not a RCThigh risk of bias
5332 Meng, 2020 1134not a RCThigh risk of bias
5345 Yan et al., 2020 1204not a RCThigh risk of bias

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons